# A bone drug to prevent breast cancer in BRCA1 carriers

Source: https://onco.cc/ideas/idea-prev-brca1-denosumab-prevention/  
OnCo record `idea-prev-brca1-denosumab-prevention` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BRCA1 breast cancers seem to grow from cells driven by the RANK signal. Denosumab blocks it and is already used for bone. A trial is testing whether it prevents these cancers.

## Summary

BRCA1 breast cancers appear to grow from progenitor cells driven by RANKL signalling, and denosumab, already used for bone, blocks it, so this idea supports completion of the ABCSG BRCA-P trial, which randomises BRCA1 carriers to denosumab or placebo with breast cancer incidence as the endpoint, and prepares implementation pathways for a positive result. Preclinical and window-of-opportunity data show reduced proliferation in carrier breast tissue. The test is the BRCA-P readout followed, if positive, by an implementation study with uptake and adherence endpoints. Being tested at scale, it addresses the bottleneck Inherited risk is mostly unidentified and links to chemoprevention, BRCA and TNBC.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Denosumab reduces breast cancer incidence in BRCA1 carriers by at least 40%.
- Rationale: Preclinical and window-of-opportunity data show reduced proliferation in carrier breast tissue.
- Proposed test: BRCA-P readout; if positive, an implementation study with uptake and adherence endpoints.
- Maturity: being-tested-at-scale
- Actor: research

## Sources

- Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017): https://doi.org/10.1200/JCO.2017.73.6314

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/)
- key papers: [National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer](https://onco.cc/key-papers/paper-childers-j-clin-oncol/), [PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers](https://onco.cc/key-papers/paper-brca-risk-reducing-surgery-jama-2010/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-brca1-denosumab-prevention.json